-
The study found that high-intensity warfarin therapy was not necessary for the prevention of recurrent thrombosis in the APA syndrome.
-
A majority of gastric fundic polyps are benign. Their presence in unscreened individuals older than 50 might warrant colonoscopy.
-
The FDA has approved tadalafil, the third phosphodiesterase type 5 inhibitor (PDE5) for the treatment of erectile dysfunction.
-
Two injectable biologic therapies, etanercept and efalizumab, have been shown to be highly effective in treating psoriasis. Etanercept has been used in rheumatoid arthritis since 1998, and efalizumab is a new agent in phase III trials. Psoriasis is a debilitating autoimmune illness, and these new therapies, while expensive, will be a welcome addition for patients suffering from a severe form of this disease.
-
Sulfonamide Antibiotics and Sulfonamide Nonantibiotics; Autoantibodies Before Onset of SLE; Prevention of VTE with Ximelagatran
-
-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
-
The following is a late-breaking trial of the American Heart Association Annual Scientific Sessions held last month in Orlando, Fla. The REVERSAL trial is covered in the pages of Internal Medicine Alert because of the abundant coverage of this issue in the lay press, as well as possible questions your patients may ask regarding this subject.
-
Labels on the 10 most frequently used herbs failed to adequately describe the ingredients, provide the correct dose of the herb, or were not interpretable by professional pharmacists.
-
A second biological agent has been approved for the treatment of moderate-to-severe plaque psoriasis.
